Skip to main content

Alpha-1 Antitrypsin Deficiency clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • A Study of Experimental INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

    open to eligible people ages 18-80

    This is an open-label, 2-part, dose-escalating, Phase 1 study of INBRX-101 (rhAAT-Fc). Part 1 will consist of single ascending dose (SAD) administration of INBRX-101 and Part 2 will consist of multiple ascending dose (MAD) administrations of INBRX-101. The planned dosing schedule is IV every 3 to 4 weeks.

    Sacramento, California and other locations

Last updated: